# A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

> **NCT05672459** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 31 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Single Injection of IVS-3001- Anti - HLA-G CAR-T cells
- **DRUG:** Fludarabine phosphate
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** leukapheresis

## Key facts

- **NCT ID:** NCT05672459
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-21
- **Primary completion:** 2026-06-29
- **Final completion:** 2029-12-29
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05672459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05672459, "A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05672459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*